Also, targeting of SPHK2 through shRNA or isoform-specific inhibitors was shown to inhibit cellular proliferation [20], and increase susceptibility of CRC to all-trans retinoic acid [21] or oxaliplatin treatment [22]. The gene discussed is SPHK2; the disease is colorectal carcinoma.